TScan Therapeutics TCRX 深 滬
已收盤 08-07 16:00:00 美东时间
0.7962
+0.033
+4.32%
華盛通- 最 高0.8041
- 今 開0.7542
- 成交量 33.63万股
- 最 低 0.7542
- 昨 收 0.7632
- 總市值 5203.23万
- 52周最高 2.57
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.716
- 委 比 -61.61%
- 總股本 6535.08万
- 歷史最高 14.71
- 量 比 0.88
- 振 幅 6.54%
- 歷史最低 0.716
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
TScan Therapeutics announced the first patient dosed in its pivotal Phase 3 ALLOHA-2 trial evaluating TSC-101 for preventing relapse in AML and MDS patients post-allo-HCT. The trial aims to assess relapse-free survival, with enrollment ongoing across the U.S., targeting a mid-2028 data readout. The company highlighted strong early results from Cohort C and expressed confidence in TSC-101's potential to improve outcomes.
07-29 11:00
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price Target
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $6 price target.
06-23 19:43
TScan Says Cancer Therapy Data Support Move to Phase 3 Trial
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today presented data from Cohort C of the ongoing ALLOHA™ Phase 1 study, evaluating TSC-10...
06-22 19:08
TScan Therapeutics Partners With Cellares To Evaluate Automated Clinical Manufacturing Of TSC-101, The Company's Lead TCR-T Therapy Candidate For Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor
06-03 21:22
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
TScan Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate, Sales $982.000K Miss $2.500M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 15.38 percent increase over losses of $(0.26) per share from
05-06 19:12
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5
Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.
03-05 21:49
Earnings Breakdown: TScan Therapeutics Q4
TScan Therapeutics (NASDAQ:TCRX) announced its Q4 earnings on Wednesday, March ...
03-04 20:12
